305 related articles for article (PubMed ID: 29121144)
1. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
Fox JJ; Gavane SC; Blanc-Autran E; Nehmeh S; Gönen M; Beattie B; Vargas HA; Schöder H; Humm JL; Fine SW; Lewis JS; Solomon SB; Osborne JR; Veach D; Sawyers CL; Weber WA; Scher HI; Morris MJ; Larson SM
JAMA Oncol; 2018 Feb; 4(2):217-224. PubMed ID: 29121144
[TBL] [Abstract][Full Text] [Related]
2. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
Vargas HA; Wassberg C; Fox JJ; Wibmer A; Goldman DA; Kuk D; Gonen M; Larson SM; Morris MJ; Scher HI; Hricak H
Radiology; 2014 Apr; 271(1):220-9. PubMed ID: 24475817
[TBL] [Abstract][Full Text] [Related]
3. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.
Bauckneht M; Bertagna F; Donegani MI; Durmo R; Miceli A; De Biasi V; Laudicella R; Fornarini G; Berruti A; Baldari S; Versari A; Giubbini R; Sambuceti G; Morbelli S; Albano D
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1198-1207. PubMed ID: 34012060
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility and Repeatability of Semiquantitative
Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
[No Abstract] [Full Text] [Related]
5. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
6. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
8. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
9. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
[TBL] [Abstract][Full Text] [Related]
10. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Conteduca V; Scarpi E; Caroli P; Salvi S; Lolli C; Burgio SL; Menna C; Schepisi G; Testoni S; Gurioli G; Paganelli G; Casadio V; Matteucci F; De Giorgi U
Sci Rep; 2017 Nov; 7(1):15541. PubMed ID: 29138500
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
Pandit-Taskar N; Veach DR; Fox JJ; Scher HI; Morris MJ; Larson SM
J Nucl Med; 2016 Oct; 57(Suppl 3):73S-78S. PubMed ID: 27694177
[TBL] [Abstract][Full Text] [Related]
12. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
Larson SM; Morris M; Gunther I; Beattie B; Humm JL; Akhurst TA; Finn RD; Erdi Y; Pentlow K; Dyke J; Squire O; Bornmann W; McCarthy T; Welch M; Scher H
J Nucl Med; 2004 Mar; 45(3):366-73. PubMed ID: 15001675
[TBL] [Abstract][Full Text] [Related]
13. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
14. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
15. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Role of volumetric parameters obtained from
Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
[TBL] [Abstract][Full Text] [Related]
18. Positron tomographic assessment of androgen receptors in prostatic carcinoma.
Dehdashti F; Picus J; Michalski JM; Dence CS; Siegel BA; Katzenellenbogen JA; Welch MJ
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):344-50. PubMed ID: 15726353
[TBL] [Abstract][Full Text] [Related]
19. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Simplified Methods for Quantification of
Kramer GM; Yaqub M; Vargas HA; Schuit RC; Windhorst AD; van den Eertwegh AJM; van der Veldt AAM; Bergman AM; Burnazi EM; Lewis JS; Chua S; Staton KD; Beattie BJ; Humm JL; Davis ID; Weickhardt AJ; Scott AM; Morris MJ; Hoekstra OS; Lammertsma AA
J Nucl Med; 2019 Sep; 60(9):1221-1227. PubMed ID: 30850488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
